Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 225,220,486 papers from all fields of science
Search
Sign In
Create Free Account
rimonabant
Known as:
5-(4-Chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-1-piperidinyl-1H-pyrazole-3-carboxamide
, N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide hydrochloride
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
6 relations
Narrower (3)
Acomplia
SR 141716A
SR141716
Broader (3)
Cannabinoid Receptor Antagonists
Piperidines
Pyrazoles
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2014
Highly Cited
2014
Cannabinoid 1 and Transient Receptor Potential Vanilloid 1 Receptors Discretely Modulate Evoked Glutamate Separately from Spontaneous Glutamate Transmission
J. Fawley
,
Mackenzie E Hofmann
,
M. Andresen
Journal of Neuroscience
2014
Corpus ID: 13038213
Action potentials trigger synaptic terminals to synchronously release vesicles, but some vesicles release spontaneously. G…
Expand
2013
2013
Dysregulation of cannabinoid CB1 receptor and associated signaling networks in brains of cocaine addicts and cocaine-treated rodents
M. Álvaro-Bartolomé
,
J. García-Sevilla
Neuroscience
2013
Corpus ID: 9685445
Highly Cited
2009
Highly Cited
2009
A randomized controlled trial of adding the nicotine patch to rimonabant for smoking cessation: efficacy, safety and weight gain.
N. Rigotti
,
D. Gonzales
,
L. Dale
,
Daniel L Lawrence
,
Yuchiao Chang
Addiction
2009
Corpus ID: 23244824
AIMS Because smoking cessation rates might be improved by combining drugs and by reducing post-cessation weight gain, we tested…
Expand
Highly Cited
2009
Highly Cited
2009
The CB1 Antagonist Rimonabant Decreases Insulin Hypersecretion in Rat Pancreatic Islets
Lisa Getty‐Kaushik
,
A. Richard
,
J. Deeney
,
S. Krawczyk
,
O. Shirihai
,
B. Corkey
Obesity
2009
Corpus ID: 30339016
Type 2 diabetes and obesity are characterized by elevated nocturnal circulating free fatty acids, elevated basal insulin…
Expand
Highly Cited
2008
Highly Cited
2008
The cannabinoid receptor‐1 antagonist rimonabant inhibits platelet activation and reduces pro‐inflammatory chemokines and leukocytes in Zucker rats
A. Schäfer
,
J. Pfrang
,
J. Neumüller
,
S. Fiedler
,
Georg Ertl
,
J. Bauersachs
British Journal of Pharmacology
2008
Corpus ID: 22110677
We investigated the effect of rimonabant on inflammation and enhanced platelet reactivity in type 2 diabetic Zucker rats, an…
Expand
Review
2007
Review
2007
Weight management for type 2 diabetes mellitus: global cardiovascular risk reduction.
Michelle H. Lee
,
L. Aronne
American Journal of Cardiology
2007
Corpus ID: 40792675
Highly Cited
2007
Highly Cited
2007
Fused-core silica column high-performance liquid chromatography/tandem mass spectrometric determination of rimonabant in mouse plasma.
Y. Hsieh
,
C. Duncan
,
J. Brisson
Analytical Chemistry
2007
Corpus ID: 30932447
A high-performance liquid chromatography (HPLC) method using a fused-core silica particle packing was evaluated to allow fast and…
Expand
2007
2007
Combination of Rimonabant and Donepezil Prolongs Spatial Memory Duration
L. Wise
,
P. Iredale
,
Rene J. Stokes
,
A. Lichtman
Neuropsychopharmacology
2007
Corpus ID: 25331297
The observations that the cannabinoid1(CB1) receptor antagonist/inverse agonist, rimonabant, and the selective noncompetitive…
Expand
Review
2006
Review
2006
Emerging strategies for increasing high-density lipoprotein.
J. Forrester
,
P. Shah
American Journal of Cardiology
2006
Corpus ID: 42418245
2003
2003
(R)-Methanandamide and delta9-tetrahydrocannabinol-induced operant rate decreases in rats are not readily antagonized by SR-141716A.
T. Järbe
,
R. Lamb
,
Qian Liu
,
A. Makriyannis
European Journal of Pharmacology
2003
Corpus ID: 45078142
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE